drugset / Trial / NCT00003451
Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced Cancer
NaSingle-groupOpen-labelTreatment
Summary
Phase I trial to study the effectiveness of combining interleukin-12 and interferon alfa in treating patients who have residual, recurrent, or metastatic malignant melanoma or other advanced cancer that has not responded to standard therapy. Interleukin-12 may stimulate a person's white blood cells to kill cancer cells. Interferon alfa may interfere with the growth of the cancer cells. Combining interleukin-12 with interferon alfa may kill more cancer cells.
Timeline
- Start
- 1998-08
- Primary completion
- 2001-12
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | interferon alfa-2b | Protein / enzyme biologic | — | Subcutaneous |
| Subject | interleukin-12 | Protein / enzyme biologic | — | Intravenous |